{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:52:46Z","timestamp":1788238366423,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the protein expression characteristics of genes employed in a recently introduced prognostic gene expression assay for patients with cutaneous melanoma (CM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We studied 37 patients with CM and 10 with benign (melanocytic) nevi (BN). Immunohistochemistry of primary tumor tissue was performed for eight proteins: COL6A6, DCD, GBP4, KLHL41, KRT9, PIP, SCGB1D2, SCGB2A2.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The protein expression of most markers investigated was relatively low (e.g., DCD, KRT9, SCGB1D2) and predominantly cytoplasmatic in melanocytes and keratinocytes. COL6A6, GBP4, and KLHL41 expression was significantly enhanced in CM when compared to BN. DCD protein expression was significantly correlated with COL6A6, GBP4, and KLHL41. GBP4 was positively correlated with KLHL41 and inversely correlated with SCGB2B2. The latter was also inversely correlated with serum S100B levels at time of initial diagnosis. The presence of SCGB1D2 expression was significantly associated with ulceration of the primary tumor. KRT9 protein expression was significantly more likely found in acral lentiginous melanoma. The presence of DCD expression was less likely associated with superficial spreading melanoma subtype but significantly associated with non-progressive disease. The absence of SCGB2A2 expression was significantly more often observed in patients who did not progress to stage III or IV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The expression levels observed were relatively low but differed in part with those found in BN. Even though we detected some significant correlations between the protein expression levels and clinical parameters (e.g., CM subtype, course of disease), there was no major concordance with the protective or risk-associated functions of the corresponding genes included in a recently introduced prognostic gene expression assay.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03779-0","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:11:53Z","timestamp":1636546313000},"page":"2673-2680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Protein expression of prognostic genes in primary melanoma and benign nevi"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7862-3695","authenticated-orcid":false,"given":"T.","family":"Gambichler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Elfering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bruckm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Stockfleth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Skrygan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. U.","family":"K\u00e4fferlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wagener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Susok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"3779_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","volume":"125","author":"TMS Amaral","year":"2020","unstructured":"Amaral TMS, Hoffmann MC, Sinnberg T, Niessner H, S\u00fclberg H, Eigentler TK, Garbe C (2020) Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. Eur J Cancer 125:38\u201345","journal-title":"Eur J Cancer"},{"issue":"2","key":"3779_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00432-012-1322-z","volume":"139","author":"G Brunner","year":"2013","unstructured":"Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, Atzpodien J (2013) A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol 139(2):249\u2013258","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"3779_CR3","doi-asserted-by":"publisher","first-page":"pky032","DOI":"10.1093\/jncics\/pky032","volume":"2","author":"G Brunner","year":"2018","unstructured":"Brunner G, Heinecke A, Falk TM, Ertas B, Bl\u00f6dorn-Schlicht N, Schulze HJ, Suter L, Atzpodien J, Berking C (2018) A prognostic gene signature expressed in primary cutaneous melanoma: synergism with conventional staging. JNCI Cancer Spectr. 2(3):pky032","journal-title":"JNCI Cancer Spectr."},{"key":"3779_CR4","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1158\/1078-0432.CCR-09-1631","volume":"15","author":"C Conway","year":"2009","unstructured":"Conway C, Mitra A, Jewell R et al (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15:6939\u20136946","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3779_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.15252\/msb.20167144","volume":"12","author":"F Edfors","year":"2016","unstructured":"Edfors F, Danielsson F, Hallstr\u00f6m BM, K\u00e4ll L, Lundberg E, Pont\u00e9n F, Forsstr\u00f6m B, Uhl\u00e9n M (2016) Gene-specific correlation of RNA and protein levels in human cells and tissues. Mol Syst Biol 12(10):883","journal-title":"Mol Syst Biol"},{"key":"3779_CR6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","volume":"47","author":"AMM Eggermont","year":"2011","unstructured":"Eggermont AMM, Robert C (2011) New drugs in melanoma: it\u2019s a whole new world. Eur J Cancer 47:2150\u20132157","journal-title":"Eur J Cancer"},{"key":"3779_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2020.08.029","volume":"140","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Bellomo D, Arias-Mejias SM, Quattrocchi E, Sominidi-Damodaran S, Bridges AG, Lehman JS, Hieken TJ, Jakub JW, Murphree DH, Pittelkow MR, Sluzevich JC, Cappel MA, Bagaria SP, Perniciaro C, Tjien-Fooh FJ, Rentroia-Pacheco B, Wever R, van Vliet MH, Dwarkasing J, Meves A (2020) Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. Eur J Cancer 140:11\u201318","journal-title":"Eur J Cancer"},{"key":"3779_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2020.10.016","volume":"143","author":"T Gambichler","year":"2021","unstructured":"Gambichler T, Tsagoudis K, Kiecker F, Reinhold U, Stockfleth E, Hamscho R, Egberts F, Hauschild A, Amaral T, Garbe C (2021a) Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. Eur J Cancer 143:11\u201318","journal-title":"Eur J Cancer"},{"issue":"11","key":"3779_CR9","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3390\/cancers13112524","volume":"13","author":"T Gambichler","year":"2021","unstructured":"Gambichler T, Abu Rached N, Tannapfel A, Becker JC, Vogt M, Skrygan M, Wieland U, Silling S, Susok L, St\u00fccker M, Meyer T, Stockfleth E, Junker K, K\u00e4fferlein HU, Br\u00fcning T, Lang K (2021b) Expression of mismatch repair proteins in Merkel cell carcinoma. Cancers (basel) 13(11):2524","journal-title":"Cancers (basel)"},{"issue":"1","key":"3779_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41467-021-21207-2","volume":"12","author":"M Garg","year":"2021","unstructured":"Garg M, Couturier DL, Nsengimana J, Fonseca NA, Wongchenko M, Yan Y, Lauss M, J\u00f6nsson GB, Newton-Bishop J, Parkinson C, Middleton MR, Bishop DT, McDonald S, Stefanos N, Tadross J, Vergara IA, Lo S, Newell F, Wilmott JS, Thompson JF, Long GV, Scolyer RA, Corrie P, Adams DJ, Brazma A, Rabbie R (2021) Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nat Commun 12(1):1137","journal-title":"Nat Commun"},{"key":"3779_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jaad.2015.01.009","volume":"72","author":"P Gerami","year":"2015","unstructured":"Gerami P, Cook RW, Russell MC et al (2015) Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol 72:780-785.e783","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3779_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472\u2013492","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3779_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2020.03.053","volume":"83","author":"BN Greenhaw","year":"2020","unstructured":"Greenhaw BN, Covington KR, Kurley SJ, Yeniay Y, Cao NA, Plasseraud KM, Cook RW, Hsueh EC, Gastman BR, Wei ML (2020) Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1479 patients. J Am Acad Dermatol 83(3):745\u2013753","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3779_CR14","doi-asserted-by":"publisher","first-page":"MMT32","DOI":"10.2217\/mmt-2019-0016","volume":"6","author":"D Grossman","year":"2019","unstructured":"Grossman D, Kim CC, Hartman RI, Berry E, Nelson KC, Okwundu N, Curiel-Lewandrowski C, Leachman SA, Swetter SM (2019) Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma Manag. 6(4):MMT32. https:\/\/doi.org\/10.2217\/mmt-2019-0016","journal-title":"Melanoma Manag."},{"key":"3779_CR15","doi-asserted-by":"publisher","first-page":"e49865","DOI":"10.1371\/journal.pone.0049865","volume":"7","author":"M Gschaider","year":"2012","unstructured":"Gschaider M, Neumann F, Peters B et al (2012) An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma. PLoS ONE 7:e49865","journal-title":"PLoS ONE"},{"key":"3779_CR16","doi-asserted-by":"publisher","first-page":"10775","DOI":"10.1038\/srep10775","volume":"5","author":"A Koussounadis","year":"2015","unstructured":"Koussounadis A, Langdon SP, Um IH, Harrison DJ, Smith VA (2015) Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Sci Rep 5:10775","journal-title":"Sci Rep"},{"issue":"1","key":"3779_CR17","doi-asserted-by":"publisher","first-page":"18336","DOI":"10.1038\/s41598-020-74996-9","volume":"10","author":"M Kwak","year":"2020","unstructured":"Kwak M, Erdag G, Slingluff CL Jr (2020) Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. Sci Rep 10(1):18336","journal-title":"Sci Rep"},{"issue":"19","key":"3779_CR18","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377(19):1813\u20131823","journal-title":"N Engl J Med"},{"issue":"8","key":"3779_CR19","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/1878-0261.12732","volume":"14","author":"F Mancuso","year":"2020","unstructured":"Mancuso F, Lage S, Rasero J, D\u00edaz-Ram\u00f3n JL, Apraiz A, P\u00e9rez-Yarza G, Ezkurra PA, Penas C, S\u00e1nchez-Diez A, Garc\u00eda-Vazquez MD, Gardeazabal J, Izu R, Mujika K, Cort\u00e9s J, Asumendi A, Boyano MD (2020) Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study. Mol Oncol 14(8):1705\u20131718","journal-title":"Mol Oncol"},{"issue":"7","key":"3779_CR20","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/ijc.30202","volume":"139","author":"I Ortega-Mart\u00ednez","year":"2016","unstructured":"Ortega-Mart\u00ednez I, Gardeazabal J, Erramuzpe A, Sanchez-Diez A, Cort\u00e9s J, Garc\u00eda-V\u00e1zquez MD, P\u00e9rez-Yarza G, Izu R, Lu\u00eds D\u00edaz-Ram\u00f3n J, de la Fuente IM, Asumendi A, Boyano MD (2016) Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma. Int J Cancer 139(7):1598\u20131607","journal-title":"Int J Cancer"},{"key":"3779_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/cncr.23147","volume":"112","author":"J Rangel","year":"2008","unstructured":"Rangel J, Nosrati M, Torabian S et al (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112:144\u2013150","journal-title":"Cancer"},{"key":"3779_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/107327480801500303","volume":"15","author":"S Ren","year":"2008","unstructured":"Ren S, Liu S, Howell P, Xi Y, Enkemann SA, Ju J, Riker AI (2008) The impact of genomics in understanding human melanoma progression and metastasis. Cancer Control 15:202\u2013215","journal-title":"Cancer Control"},{"key":"3779_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrclinonc.2013.246","volume":"11","author":"D Schadendorf","year":"2014","unstructured":"Schadendorf D, Hauschild A (2014) Melanoma\u2014the run of success continues. Nat Rev Clin Oncol 11:75\u201376","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"3779_CR24","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.4161\/cbt.4.9.2165","volume":"4","author":"AP Smith","year":"2005","unstructured":"Smith AP, Hoek K, Becker D (2005) Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi\/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 4(9):1018\u20131029","journal-title":"Cancer Biol Ther"},{"key":"3779_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03630-6","author":"L Susok","year":"2021","unstructured":"Susok L, Gambichler T (2021) Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma. J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-021-03630-6","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"3779_CR26","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1007\/s00432-021-03562-1","volume":"147","author":"L Susok","year":"2021","unstructured":"Susok L, St\u00fccker M, Bechara FG, Stockfleth E, Gambichler T (2021) Multivariate analysis of prognostic factors in patients with nodular melanoma. J Cancer Res Clin Oncol 147(9):2759\u20132764","journal-title":"J Cancer Res Clin Oncol"},{"key":"3779_CR27","first-page":"7526204","volume":"2020","author":"J Wang","year":"2020","unstructured":"Wang J, Kong PF, Wang HY, Song D, Wu WQ, Zhou HC, Weng HY, Li M, Kong X, Meng B, Chen ZK, Chen JJ, Li CY, Shao JY (2020) Identification of a gene-related risk signature in melanoma patients using bioinformatic profiling. J Oncol 2020:7526204","journal-title":"J Oncol"},{"key":"3779_CR28","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/onc.2013.30","volume":"33","author":"J Wardwell-Ozgo","year":"2014","unstructured":"Wardwell-Ozgo J, Dogruluk T, Gifford A et al (2014) HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 33:1017\u20131026","journal-title":"Oncogene"},{"issue":"19","key":"3779_CR29","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824\u20131835","journal-title":"N Engl J Med"},{"issue":"23","key":"3779_CR30","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1002\/cncr.29634","volume":"121","author":"SA Weiss","year":"2015","unstructured":"Weiss SA, Hanniford D, Hernando E, Osman I (2015) Revisiting determinants of prognosis in cutaneous melanoma. Cancer 121(23):4108\u20134123","journal-title":"Cancer"},{"key":"3779_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/jnci\/djj103","volume":"98","author":"V Winnepenninckx","year":"2006","unstructured":"Winnepenninckx V, Lazar V, Michiels S et al (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472\u2013482","journal-title":"J Natl Cancer Inst"},{"key":"3779_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fimmu.2020.00224","volume":"11","author":"L Xu","year":"2020","unstructured":"Xu L, Pelosof L, Wang R, McFarland HI, Wu WW, Phue JN, Lee CT, Shen RF, Juhl H, Wu LH, Alterovitz WL, Petricon E, Rosenberg AS (2020) NGS evaluation of colorectal cancer reveals interferon gamma dependent expression of immune checkpoint genes and identification of novel IFN\u03b3 induced genes. Front Immunol 11:224. https:\/\/doi.org\/10.3389\/fimmu.2020.00224","journal-title":"Front Immunol"},{"issue":"21","key":"3779_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026017","volume":"100","author":"W Yingjuan","year":"2021","unstructured":"Yingjuan W, Li Z, Wei C, Xiaoyuan W (2021) Identification of prognostic genes and construction of a novel gene signature in the skin melanoma based on the tumor microenvironment. Medicine (BAltimore) 100(21):e26017. https:\/\/doi.org\/10.1097\/MD.0000000000026017","journal-title":"Medicine (BAltimore)"},{"key":"3779_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.12.002","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Liu W, Gotlieb V (2016) The rapidly evolving therapies for advanced melanoma\u2014towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol\/hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.12.002","journal-title":"Crit Rev Oncol\/hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03779-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03779-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03779-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:12:43Z","timestamp":1663056763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03779-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3779"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03779-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This non-interventional study was approved by Institutional Review Board at the Ruhr-University Bochum (IRB Study ID #16-5985). All procedures performed in studies involving human participants or their data were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}}]}}